Endothelin A Receptor Antagonists
"Endothelin A Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds and drugs that bind to and inhibit or block the activation of ENDOTHELIN A RECECPTORS.
| Descriptor ID |
D065130
|
| MeSH Number(s) |
D27.505.519.364.500
|
| Concept/Terms |
Endothelin A Receptor Antagonists- Endothelin A Receptor Antagonists
- Blockers, Endothelin A Receptor
- Endothelin Type A Receptor Antagonists
- Antagonists, Endothelin A Receptor
- Endothelin A Receptor Blockers
|
Below are MeSH descriptors whose meaning is more general than "Endothelin A Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Endothelin A Receptor Antagonists".
This graph shows the total number of publications written about "Endothelin A Receptor Antagonists" by people in this website by year, and whether "Endothelin A Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Endothelin A Receptor Antagonists" by people in Profiles.
-
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019 05 11; 393(10184):1937-1947.
-
The Endothelin-A Receptor Antagonist Zibotentan Induces Damage to the Nasal Olfactory Epithelium Possibly Mediated in Part through Type 2 Innate Lymphoid Cells. Toxicol Pathol. 2019 02; 47(2):150-164.
-
Baseline characteristics and enrichment results from the SONAR trial. Diabetes Obes Metab. 2018 08; 20(8):1829-1835.
-
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab. 2018 06; 20(6):1369-1376.
-
Endothelin Receptor A Antagonism Prevents Damage to Glycogen-Rich Placental Cells Following Uterine Ischemia-Reperfusion in the Rat. Reprod Sci. 2016 11; 23(11):1518-1525.
-
Endothelin Receptor A Antagonism and Fetal Growth in Endothelial Nitric Oxide Synthase Gene Knockout Maternal and Fetal Mice. Reprod Sci. 2016 08; 23(8):1028-36.
-
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013 May 07; 158(9):641-9.
-
The significance of endothelin in platelet-activating factor-induced fetal growth restriction. Reprod Sci. 2012 Nov; 19(11):1175-80.
-
Endothelin receptor antagonist has limited access to the fetal compartment during chronic maternal administration late in pregnancy. Life Sci. 2012 Oct 15; 91(13-14):583-6.
-
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Oct 24; 374(9699):1423-31.